QQQ $ 585.21 $ -26.46 (-4.33 %)
DIA $ 458.00 $ -8.67 (-1.86 %)
SPY $ 652.36 $ -20.54 (-3.05 %)
TLT $ 89.29 $ 0.30 (0.34 %)
GLD $ 374.71 $ -0.47 (-0.13 %)
$ 0.787283
-- x --
-- x --
-- - --
$ 0.17 - $ 2.23
3,203
na
2.51M
$ 0.11
$ 0.41
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-13-2025 09-30-2025 10-Q
2 08-14-2025 06-30-2025 10-Q
3 05-15-2025 03-31-2025 10-Q
4 03-31-2025 12-31-2024 10-K
5 11-14-2024 09-30-2024 10-Q
6 08-09-2024 06-30-2024 10-Q
7 05-15-2024 03-31-2024 10-Q
8 03-18-2024 12-31-2023 10-K
9 11-13-2023 09-30-2023 10-Q
10 08-11-2023 06-30-2023 10-Q
11 05-12-2023 03-31-2023 10-Q
12 03-31-2023 12-31-2022 10-K
13 11-10-2022 09-30-2022 10-Q
14 08-15-2022 06-30-2022 10-Q
15 05-16-2022 03-31-2022 10-Q
16 03-25-2022 12-31-2021 10-K
17 11-15-2021 09-30-2021 10-Q
18 08-16-2021 06-30-2021 10-Q
19 05-17-2021 03-31-2021 10-Q
20 03-31-2021 12-31-2020 10-K
21 11-04-2020 09-30-2020 10-Q
22 08-14-2020 06-30-2020 10-Q
23 05-11-2020 03-31-2020 10-Q
24 03-30-2020 12-31-2019 10-K
25 11-13-2019 09-30-2019 10-Q
26 08-14-2019 06-30-2019 10-Q
27 05-13-2019 03-31-2019 10-Q
28 03-12-2019 12-31-2018 10-K
29 11-14-2018 09-30-2018 10-Q
30 08-14-2018 06-30-2018 10-Q
31 05-03-2018 03-31-2018 10-Q
32 03-01-2018 12-31-2017 10-K
33 11-09-2017 09-30-2017 10-Q
34 08-11-2017 06-30-2017 10-Q
35 05-12-2017 03-31-2017 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Avenue Therapeutics, Inc. (OTC:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on...

 avenue-therapeutics-q2-eps-011-up-from-643-yoy-sales-1404m

Avenue Therapeutics (OTC:ATXI) reported quarterly earnings of $0.11 per share. This is a 101.71 percent increase over losses of...

 venue-therapeutics-files-for-mixed-shelf-of-upto-35m

- SEC Filing

 avenue-therapeutics-q3-eps-192-misses-094-estimate

Avenue Therapeutics (NASDAQ:ATXI) reported quarterly losses of $(1.92) per share which missed the analyst consensus estimate of...

 avenue-therapeutics-q2-eps-643-misses-105-estimate

Avenue Therapeutics (NASDAQ:ATXI) reported quarterly losses of $(6.43) per share which missed the analyst consensus estimate of...

 avenue-therapeutics-q1-eps-1540-misses-900-estimate

Avenue Therapeutics (NASDAQ:ATXI) reported quarterly losses of $(15.40) per share which missed the analyst consensus estimate o...

 avenue-therapeutics-may-offer-shares-of-common-stock-having-offering-price-of-up-to-39m-from-time-to-time-through-agent

- SEC Filing

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION